Canada markets open in 7 hours
  • S&P/TSX

    18,457.78
    +76.82 (+0.42%)
     
  • S&P 500

    3,821.35
    -20.59 (-0.54%)
     
  • DOW

    31,802.44
    +306.14 (+0.97%)
     
  • CAD/USD

    0.7905
    +0.0006 (+0.07%)
     
  • CRUDE OIL

    64.51
    -0.54 (-0.83%)
     
  • BTC-CAD

    67,952.80
    +3,579.84 (+5.56%)
     
  • CMC Crypto 200

    1,082.17
    +57.96 (+5.66%)
     
  • GOLD FUTURES

    1,690.30
    +12.30 (+0.73%)
     
  • RUSSELL 2000

    2,202.98
    +10.77 (+0.49%)
     
  • 10-Yr Bond

    1.5960
    0.0000 (0.00%)
     
  • NASDAQ futures

    12,401.50
    +104.25 (+0.85%)
     
  • VOLATILITY

    25.47
    +0.81 (+3.28%)
     
  • FTSE

    6,719.13
    +88.61 (+1.34%)
     
  • NIKKEI 225

    29,027.94
    +284.69 (+0.99%)
     
  • CAD/EUR

    0.6658
    -0.0004 (-0.06%)
     

If You Had Bought ImmunoPrecise Antibodies (CVE:IPA) Shares Three Years Ago You'd Have Earned 555% Returns

Simply Wall St
·3 min read

ImmunoPrecise Antibodies Ltd. (CVE:IPA) shareholders might be concerned after seeing the share price drop 14% in the last week. But that doesn't change the fact that the returns over the last three years have been spectacular. In fact, the share price has taken off in that time, up 555%. So you might argue that the recent reduction in the share price is unremarkable in light of the longer term performance. Only time will tell if there is still too much optimism currently reflected in the share price.

We love happy stories like this one. The company should be really proud of that performance!

See our latest analysis for ImmunoPrecise Antibodies

Because ImmunoPrecise Antibodies made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

In the last 3 years ImmunoPrecise Antibodies saw its revenue grow at 42% per year. That's much better than most loss-making companies. And it's not just the revenue that is taking off. The share price is up 87% per year in that time. Despite the strong run, top performers like ImmunoPrecise Antibodies have been known to go on winning for decades. So we'd recommend you take a closer look at this one, or even put it on your watchlist.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

This free interactive report on ImmunoPrecise Antibodies' balance sheet strength is a great place to start, if you want to investigate the stock further.

A Different Perspective

We're pleased to report that ImmunoPrecise Antibodies rewarded shareholders with a total shareholder return of 512% over the last year. That gain actually surpasses the 87% TSR it generated (per year) over three years. Given the track record of solid returns over varying time frames, it might be worth putting ImmunoPrecise Antibodies on your watchlist. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 4 warning signs for ImmunoPrecise Antibodies (1 makes us a bit uncomfortable) that you should be aware of.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on CA exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.